Inhibition of endotoxin effects on cultured human middle ear epithelium by bactericidal permeability-increasing

M J Nell1, B M Albers-Op 't Hof, H K Koerten

  • 1Department of Otorhinolaryngology, Leiden University Medical Center, The Netherlands.

Abstract

Insights

Recombinant bactericidal/permeability-increasing (BPI) protein 21 (rBPI21) effectively inhibited endotoxin-induced morphologic changes in human middle ear epithelial cells, suggesting its potential for treating otitis media with effusion.

Area of Science:

  • Otolaryngology
  • Cell Biology
  • Immunology

Background:

  • Endotoxin causes middle ear epithelial changes, impairing mucociliary clearance and potentially leading to otitis media with effusion (OME).
  • Bactericidal/permeability-increasing (BPI) protein binds endotoxin and is found in neutrophil granules.
  • rBPI21 is a recombinant analog of BPI investigated for its endotoxin-inhibiting properties.

Purpose of the Study:

  • To investigate the capacity of rBPI21 to inhibit endotoxin-induced morphologic changes in cultured human middle ear epithelium.
  • To evaluate the impact of rBPI21 on mucociliary clearance system (MCS) components.

Main Methods:

  • Cultured human middle ear epithelium was exposed to endotoxin and rBPI21.
  • Morphologic assessments included light microscopy, scanning electron microscopy, and transmission electron microscopy.
  • Evaluated parameters were ciliated and secretory cell counts, mucosal layer thickness, and cell size after 4 weeks.

Main Results:

  • Endotoxin exposure led to increased mucosal thickness and secretory cells.
  • rBPI21 significantly diminished or prevented these endotoxin-induced morphologic alterations.
  • Cell size and ciliated cell counts remained largely unaffected by endotoxin or rBPI21.

Conclusions:

  • rBPI21 demonstrates efficacy in inhibiting endotoxin-induced morphologic changes in middle ear epithelium.
  • rBPI21 shows promise as a novel therapeutic agent for otitis media with effusion (OME).
  • Further research is warranted to explore rBPI21's therapeutic potential in OME treatment.